SLC5A2 and chronic kidney disease: In three outcome trials assessing the SGLT2 inhibitors in CKD patients with diabetic and non-diabetic CKD (CREDENCE trial with canagliflozin, DAPA-CKD trial with dapagliflozin, and SCORED trial with sotagliflozin), significant renal-protective outcomes were observed (Bhatt et al. 2020; Heerspink et al. 2020; Mosenzon et al. 2019; Neal et al. 2017a; Perkovic et al. 2019; Wiviott et al. 2018; Zinman et al. 2015a).